Skip to main content
OpenTrials
Completed

NCT Number: NCT00793767

Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration

Recently EPO receptors have been found in human muscle tissue, but what is still not known is the physiological role of these receptors. In this study the researchers want to investigate if there is any effect of a acute administration of EPO on insulin resistance and/or substrate metabolism in muscle tissue.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Insulin Sensitivity Glucose Metabolism Disorders Hyperinsulinism Insulin Resistance Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Medicinsk forsknings laboratorium

Århus C, 8000, Denmark

About this study

Recently EPO receptors have been found in human muscle tissue, but what is still not known is what the physiological role of these receptors are. It has previously been shown that Growth Hormone mediate insulin resistance. The GH receptor and EPO receptor belong to the same family of cytokine receptors, and thereby share many of the same signalling pathways. In this study we want to investigate if there is a similar effect on insulin resistance and/or substrate metabolism after acute administration of EPO in human muscle tissue. Different signalling pathways are investigated på western blotting, and insulin sensitivity are measured be a hyperinsulinemic euglycemic clamp, and substrate metabolism is measured by the forearm model.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy persons
  • Between 18 and 30 years
  • Normal weight (BMI: 18-25)

Exclusion criteria

  • Severe heart disease (NYHA 3)
  • Uncontrolled hypertension
  • Previous cerebrovascular disease
  • Proliferative retinopathy
  • Diabetes
  • Musculo-skeletal diseases

Treatment and study plan

Erythropoietin

Drug

bolus of 400 IU/kg

Placebo (saline)

Drug

i.v

Primary outcomes

  1. Insulin sensitivity

    Time frame: 4 and 6 hours post

Secondary outcomes

  1. Substrate metabolism

    Time frame: 4 and 6 hours post

Sponsors and collaborators

Lead sponsor

Aarhus University Hospital

Other

Registry information

Official study title

Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men

Important dates

Study start
2009
Primary completion
2009
First posted
Nov 19, 2008
Registry last updated
May 29, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.